Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Memantine has negligible benefits in mild to moderate Alzheimer's disease

Research output: Contribution to journalArticle

5 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)21-22
Number of pages2
JournalAlzheimer's and Dementia
Volume3
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Memantine
Meta-Analysis
Alzheimer Disease

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

@article{93fd0051fed543e2907c3ff50ab63845,
title = "Commentary on {"}Meta-analysis of six-month memantine trials in Alzheimer's disease.{"} Memantine has negligible benefits in mild to moderate Alzheimer's disease",
author = "Knopman, {David S}",
year = "2007",
month = "1",
doi = "10.1016/j.jalz.2006.10.002",
language = "English (US)",
volume = "3",
pages = "21--22",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Memantine has negligible benefits in mild to moderate Alzheimer's disease

AU - Knopman, David S

PY - 2007/1

Y1 - 2007/1

UR - http://www.scopus.com/inward/record.url?scp=33846125247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846125247&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2006.10.002

DO - 10.1016/j.jalz.2006.10.002

M3 - Article

VL - 3

SP - 21

EP - 22

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 1

ER -